Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Subscribe To Our Newsletter & Stay Updated